249 related articles for article (PubMed ID: 36139624)
21. Uterine Carcinosarcomas - Diagnosis and Management.
Denschlag D; Ulrich UA
Oncol Res Treat; 2018; 41(11):675-679. PubMed ID: 30317231
[TBL] [Abstract][Full Text] [Related]
22. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.
Bansal N; Herzog TJ; Seshan VE; Schiff PB; Burke WM; Cohen CJ; Wright JD
Obstet Gynecol; 2008 Jul; 112(1):64-70. PubMed ID: 18591309
[TBL] [Abstract][Full Text] [Related]
23. Uterine carcinosarcoma: A review of the literature.
Cantrell LA; Blank SV; Duska LR
Gynecol Oncol; 2015 Jun; 137(3):581-8. PubMed ID: 25805398
[TBL] [Abstract][Full Text] [Related]
24. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.
Resnick MB; Sabo E; Kondratev S; Kerner H; Spagnoli GC; Yakirevich E
Int J Cancer; 2002 Sep; 101(2):190-5. PubMed ID: 12209997
[TBL] [Abstract][Full Text] [Related]
25. Cervical carcinosarcoma: a case report.
Abidi A; Menn K; Sherman A; Konia T; Azodi M
J Reprod Med; 2008 Feb; 53(2):138-40. PubMed ID: 18357808
[TBL] [Abstract][Full Text] [Related]
26. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
27. Carcinosarcoma of the uterus: MRI findings including diffusion-weighted imaging and MR spectroscopy.
Takeuchi M; Matsuzaki K; Harada M
Acta Radiol; 2016 Oct; 57(10):1277-84. PubMed ID: 26787673
[TBL] [Abstract][Full Text] [Related]
28. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.
Cicin İ; Özatlı T; Türkmen E; Özturk T; Özçelik M; Çabuk D; Gökdurnalı A; Balvan Ö; Yıldız Y; Şeker M; Özdemir N; Yapar B; Tanrıverdi Ö; Günaydin Y; Menekşe S; Öksüzoğlu B; Aksoy A; Erdogan B; Bekir Hacıoglu M; Arpaci E; Sevinç A
Balkan Med J; 2016 Sep; 33(5):517-524. PubMed ID: 27761279
[TBL] [Abstract][Full Text] [Related]
29. A Study of Prognostic Factors of Chinese Patients with Gynecologic Tract Carcinosarcomas Prognosis of Gynecologic Carcinosarcomas.
Ye D; Shen HR; Yao L
Cancer Manag Res; 2020; 12():10781-10788. PubMed ID: 33149683
[TBL] [Abstract][Full Text] [Related]
30. Novel targeted therapies in ovarian and uterine carcinosarcomas.
Han C; Altwerger G; Menderes G; Haines K; Feinberg J; Lopez S; Manzano A; Varughese J; Santin AD
Discov Med; 2018 Jun; 25(140):309-319. PubMed ID: 30021104
[TBL] [Abstract][Full Text] [Related]
31. [Sarcomas and mixed mesodermal tumors of the uterus].
Günthert AR
Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
[TBL] [Abstract][Full Text] [Related]
32. Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
Song T; Choi CH; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS
J Gynecol Oncol; 2011 Jun; 22(2):83-8. PubMed ID: 21860733
[TBL] [Abstract][Full Text] [Related]
33. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
[TBL] [Abstract][Full Text] [Related]
34. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?
McCluggage WG
J Clin Pathol; 2002 May; 55(5):321-5. PubMed ID: 11986333
[TBL] [Abstract][Full Text] [Related]
35. A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract.
Pors J; Cheng A; Leo JM; Kinloch MA; Gilks B; Hoang L
Am J Surg Pathol; 2018 Dec; 42(12):1596-1606. PubMed ID: 30148742
[TBL] [Abstract][Full Text] [Related]
36. Oncogene alterations in endometrial carcinosarcomas.
Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
[TBL] [Abstract][Full Text] [Related]
37. The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies.
Yahya MA; Sharon SM; Hantisteanu S; Hallak M; Bruchim I
Front Endocrinol (Lausanne); 2018; 9():297. PubMed ID: 29922232
[TBL] [Abstract][Full Text] [Related]
38. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
[TBL] [Abstract][Full Text] [Related]
39. Prognostic features of surgical stage I uterine carcinosarcoma.
Ferguson SE; Tornos C; Hummer A; Barakat RR; Soslow RA
Am J Surg Pathol; 2007 Nov; 31(11):1653-61. PubMed ID: 18059221
[TBL] [Abstract][Full Text] [Related]
40. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
